|
Overview
Metabolomics has shown itself to be of great value in the development and testing of therapeutics. The science provides unique insights for the identification of biomarkers for toxicity, disease states, absorption, bioavailability, and many other areas. However, several problems continue to plague the field, including the integration of data from proteomics, genomics, transcriptomics and metabolomics, as well as how best to use the technology for accurate and usable results.
This conference will focus on the application of metabolomics to drug development, clinical outcomes, and ways to improve the use of available technology for more meaningful solutions to metabolomics questions.
| Sessions Include:
4 Application of Metabolic Profiling to Drug Development
4 Metabolomics and Biomarkers
4 Metabolomics in the Clinic
4 Data Mining and
-omics Data Integration
4 Improving Technology Performance |
Scientific Advisory Board
-
Richard D. Beger, Ph.D., Branch Chief, Center for Metabolomics, National Center for Toxicological Research, FDA
-
Sarah L.
Heald, Ph.D., Research Fellow, Department of Chemistry
Research, Bayer HealthCare, Pharmaceuticals
-
Dr. Laurent-Bernard Fay,
Head Leader Metabonomics & Biomarkers, Bioanalytical Science, Nestle Research Center
-
Craig Thomas, Ph.D., Head, Investigative Toxicology, Eli Lilly & Company
-
Andrew W. Nicholls, Ph.D.,
Principal Scientist, GlaxoSmithKline - UK
| Visionary
Presentations: |
Metabolomics:
An Evolutionary View of Its Past, Present, and Future
Chris Beecher, Ph.D., President, Metabolic Analyses Inc.
Metabolic Profiling and Biomarkers: Opportunities and
Challenges in Drug Discovery and Development
Rakesh Dixit, Ph.D., DABT., Senior Director and Head,
Toxicology Department, MedImmune Incorporated |
|
